GlassScriptPhysician profile
David Gasalberti
NPI 1639565948
$3,477.01
in general payments reported to CMS, 2019-2025
32 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2021: $251 · 2022: $581 · 2023: $1,531 · 2024: $495 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,267 · Education: $85.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,267.20 |
| Education | $85.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $837.92 | 2023-2025 | Optune, Optune Gio |
| Seagen INC. | $443.02 | 2021-2023 | Tukysa, Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $389.94 | 2021-2024 | |
| Boston Scientific Corporation | $181.51 | 2019-2023 | |
| Eisai INC. | $172.81 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $169.00 | 2019-2023 | Enhertu, Calquence |
| E.R. Squibb & Sons, L.L.C. | $128.24 | 2022-2023 | Opdivo |
| Novartis Pharmaceuticals Corporation | $122.42 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $114.26 | 2022-2023 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $106.89 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $73.83 | 2023 | Libtayo |
| Morphosys, US INC. | $73.45 | 2023-2024 | Monjuvi |
| Teleflex LLC | $64.82 | 2025 | Barrigel |
| Janssen Biotech, INC. | $61.90 | 2022-2023 | Imbruvica |
| Daiichi Sankyo INC. | $59.21 | 2023 | Enhertu |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $57.54 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $49.93 | 2022 | |
| Sumitomo Pharma America, INC. | $44.57 | 2023-2024 | Orgovyx |
| Tactile Systems Technology INC | $41.62 | 2024 | Entre Plus, Flexitouch Plus |
| Takeda Pharmaceuticals U.S.A., INC. | $33.01 | 2022 | |
| Genmab U.S., INC. | $29.41 | 2023 | Epkinly, Tivdak |
| Pfizer INC. | $29.16 | 2021-2023 | |
| Myovant Sciences INC. | $27.59 | 2022 | |
| Siemens Medical Solutions USA, INC. | $25.99 | 2023 | Varian Ethos Treatment Planning |
| Mevion_medical_systems_inc | $22.76 | 2023 | Pts250 |
| Dendreon Pharmaceuticals LLC | $20.36 | 2021 | |
| Progenics Pharmaceuticals, INC. | $20.06 | 2024 | |
| Glaxosmithkline, LLC. | $16.95 | 2023 | Zejula, Jemperli |
| Telix Pharmaceuticals | $16.63 | 2024 | Illuccix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.84 | 2022 | |
| Amgen INC. | $14.44 | 2021 | |
| Coherus Oncology, INC. | $12.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gasalberti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.